- D Gareth Evans, MD, FRCP
D Gareth Evans, MD, FRCP
- Cancer Lead and Consultant in Clinical Genetics
- Genetic Medicine
- Manchester Academic Health Sciences Centre
- Central Manchester University Hospitals NHS Foundation Trust
Li-Fraumeni syndrome is an inherited autosomal dominant disorder that is manifested by a wide range of malignancies that appear at an unusually early age [1,2]. Li-Fraumeni syndrome is also known as the Sarcoma, Breast, Leukemia, and Adrenal Gland (SBLA) cancer syndrome. This cancer predisposition syndrome is inherited as an autosomal dominant disorder and is associated with abnormalities in the tumor protein p53 gene (TP53).
The molecular pathogenesis of Li-Fraumeni syndrome, its clinical manifestations, diagnosis, management, and implications for genetic counseling of patients and their families are reviewed here. The treatment of specific malignancies that develop in these patients is discussed separately.
The only gene that has been definitively associated with Li-Fraumeni syndrome is TP53, which is located on chromosome 17p13.1 [1-3]. Although mutations at two other locations (one at 1q23 and the CHEK2 locus at 22q12.1) have been postulated, there has been no validation of the 1q23 linkage, and CHEK2 has been discounted as a Li-Fraumeni gene . TP53 is a tumor suppressor gene that has a major role in determining the fate of cells that contain damaged DNA. The gene product, tumor protein p53, can delay cell cycle progression, permitting an opportunity for DNA repair or initiation of programmed cell death (apoptosis). In the absence of the normal activated p53 protein, cells containing damaged DNA can survive and proliferate, which contributes to malignant transformation.
A variety of molecular techniques have been used to detect mutations in the TP53 gene, including sequence analysis of all or part of the gene, and techniques for detecting gene deletion or duplication. Over 300 distinct germline mutations of TP53 have been identified . Missense mutations comprise the majority of these; most occur in exons 5-8, which are the DNA-binding region of the gene.
Li-Fraumeni syndrome is an autosomal dominant disease in which affected individuals have inherited one abnormal copy of the TP53 gene. In tumors from these patients, the second allele of TP53 is either somatically mutated or deleted, leaving cells with no functional gene product.
- Malkin D. Li-fraumeni syndrome. Genes Cancer 2011; 2:475.
- Schneider K, Garber J. Li-Fraumeni syndrome. In: GeneReviews [Internet], Pagon RA, Bird TC, Dolan CR, Stephens K. (Eds), University of Washington, Seattle 2010.
- Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet 2008; 45:63.
- Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008; :1.
- Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747.
- Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.
- Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009; 27:1250.
- Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 2015.
- Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90:606.
- Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001; 96:238.
- Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010; 5:104.
- Boyle JM, Spreadborough A, Greaves MJ, et al. The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. Br J Cancer 2001; 85:293.
- Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82:1932.
- Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992; 51:344.
- Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016; 122:3673.
- Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006; 66:8287.
- Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010; 47:771.
- Evans DG, Moran A, Hartley R, et al. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 2010; 102:1091.
- Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 1999; 65:995.
- Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63:6643.
- Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012; 118:1387.
- Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54:1298.
- Libé R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005; 153:477.
- Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009; 27:e108.
- Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001; 38:43.
- Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25:101.
- Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47:421.
- Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005; 103:2391.
- Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 2010; 28:3008.
- Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011; 12:559.
- Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016.
- NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org (Accessed on May 14, 2013).
- Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 2012; 205:479.
- Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769.
- MOLECULAR PATHOGENESIS
- CLINICAL MANIFESTATIONS
- Spectrum of malignancies and age at onset
- Multiple cancers
- Radiation-associated cancers
- Lifetime risk of cancer
- SPECIFIC MALIGNANCIES
- Breast cancer
- Brain tumors
- Adrenocortical carcinomas
- DIAGNOSTIC CRITERIA
- DIFFERENTIAL DIAGNOSIS
- BRCA1 and BRCA2 mutations
- Mismatch repair cancer (Lynch) syndrome
- Who to test for TP53 mutation
- Cancer management
- Cancer surveillance strategy
- SUMMARY AND RECOMMENDATIONS